Form 4: Actinium Pharmaceuticals Director June Almenoff Receives Stock Options
SEC Form 4
June Almenoff, a director of Actinium Pharmaceuticals, was granted stock options to purchase 50,000 shares of common stock.
Summary
- June Almenoff, a director at Actinium Pharmaceuticals, received stock options on November 1, 2024.
- The options grant is for 50,000 shares of Actinium Pharmaceuticals' common stock.
- The exercise price for the options is $1.71 per share, which was the closing stock price on the grant date.
- The options vest over time, with 28% vesting after 12 months and the remaining 72% vesting monthly thereafter until fully vested.
- The options expire on November 1, 2034.
Sentiment
Score: 6
Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of the stock option grant and earliest transaction. |
| 11/05/2024 | Date of the signature on the Form 4 filing. |
| 11/01/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.